Holen Sie sich die Stockscreener-App
75.74
2.62%
-2.04
Handel nachbörslich:
75.66
-0.08
-0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALC?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$77.78
Offen:
$76.85
24-Stunden-Volumen:
1.71M
Relative Volume:
1.09
Marktkapitalisierung:
$36.92B
Einnahmen:
$10.40B
Nettoeinkommen (Verlust:
$980.00M
KGV:
38.35
EPS:
1.9749
Netto-Cashflow:
$1.61B
1W Leistung:
-6.23%
1M Leistung:
-7.96%
6M Leistung:
-2.64%
1J Leistung:
-16.69%
1-Tages-Spanne:
$75.74
$77.01
1-Wochen-Bereich:
$75.74
$80.25
52-Wochen-Spanne:
$71.55
$99.20
Alcon Inc Stock (ALC) Company Profile
Compare ALC vs ISRG, BDX, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
75.74 | 37.92B | 10.40B | 980.00M | 1.61B | 1.9749 |
|
ISRG
Intuitive Surgical Inc
|
477.73 | 171.69B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
158.08 | 45.59B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
MDLN
Medline Inc
|
42.26 | 33.89B | 28.43B | 1.16B | 1.26B | 1.4457 |
|
RMD
Resmed Inc
|
227.88 | 33.59B | 5.40B | 1.49B | 1.78B | 10.12 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-01-30 | Eingeleitet | William Blair | Mkt Perform |
| 2026-01-20 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2026-01-09 | Herabstufung | Stifel | Buy → Hold |
| 2025-12-11 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-08-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-05-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-05-14 | Bestätigt | BTIG Research | Buy |
| 2025-03-28 | Bestätigt | Needham | Buy |
| 2025-03-25 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-24 | Bestätigt | Needham | Buy |
| 2025-01-10 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | Bestätigt | Needham | Buy |
| 2024-11-12 | Bestätigt | Needham | Buy |
| 2024-10-10 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-10 | Eingeleitet | Goldman | Buy |
| 2024-03-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | Eingeleitet | Bernstein | Outperform |
| 2023-12-18 | Herabstufung | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | Eingeleitet | Stifel | Buy |
| 2023-12-04 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-10 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | Hochstufung | Societe Generale | Sell → Hold |
| 2022-12-22 | Eingeleitet | Mizuho | Buy |
| 2022-11-17 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-08-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-05-13 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-05-12 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | Eingeleitet | Needham | Buy |
| 2022-03-11 | Eingeleitet | BofA Securities | Buy |
| 2022-01-18 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Eingeleitet | Oppenheimer | Perform |
| 2021-07-14 | Eingeleitet | Deutsche Bank | Buy |
| 2021-05-06 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-03-22 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-11-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-07-06 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-07-06 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | Hochstufung | Argus | Hold → Buy |
| 2020-03-24 | Hochstufung | Societe Generale | Sell → Hold |
| 2020-03-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-26 | Hochstufung | Berenberg | Hold → Buy |
| 2020-01-08 | Eingeleitet | Argus | Hold |
| 2019-10-29 | Eingeleitet | Stephens | Equal-Weight |
| 2019-08-21 | Bestätigt | BofA/Merrill | Neutral |
| 2019-06-24 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-06-14 | Eingeleitet | BTIG Research | Neutral |
| 2019-05-10 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-05-02 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Alcon Inc Aktie (ALC) Neueste Nachrichten
Alcon and Lensar terminate proposed merger after FTC pressure - Eyes On Eyecare
EV Market: Can Alcon Inc outperform in the next rally2026 Price Targets & Long-Term Growth Stock Strategies - baoquankhu1.vn
Lensar stock slumps after hours on ending merger deal with Alcon over FTC pushback - MSN
Alcon And LENSAR: Why The Broken Merger Creates Two Different Buy Cases (NYSE:ALC) - Seeking Alpha
Alcon and Lensar Agree to Terminate Merger Agreement - VisionMonday.com
ACQUISITIONS & MERGERS NEWS: FTC successfully blocks Alcon-LENSAR merger in cataract surgery laser market - VitalLaw.com
BTIG upgrades Lensar stock rating to buy after Alcon deal ends - Investing.com
Alcon Drops $430M Lensar Deal Under Pressure From FTC - Law360
Alcon abandons effort to purchase LENSAR after FTC scrutiny - MedTech Dive
LENSAR Terminates Merger Agreement with Alcon Following FTC Challenge, Retains $10M Deposit and Announces Strategic Update - Minichart
Lensar Share Slide on Terminated Merger Deal With Alcon - marketscreener.com
Alcon, LENSAR terminate merger agreement after US FTC opposition - MLex
Alcon, LENSAR Halt Merger Deal Amid FTC Scrutiny - Medical Product Outsourcing
US FTC stops proposed merger of Alcon, LENSAR - MLex
US FTC Says It Stops Proposed Merger Of Cataract-Surgery Device Makers Lensar And Alcon - TradingView
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review - Benzinga
LENSAR Ends Alcon Merger, Plans Strategic Update - TipRanks
Lensar and Alcon Sign Termination Agreement; Lensar Retains $10 Million Deposit - TradingView
LENSAR (NASDAQ: LNSR) terminates Alcon merger, retains $10M and plans strategy update - Stock Titan
Alcon Inc stock terminates Lensar merger amid US regulatory hurdles, shifts focus to core growth - AD HOC NEWS
Lensar to terminate Alcon merger agreement - Yahoo Finance
Switzerland: Alcon and Lensar agree to terminate merger agreement - Investors in Healthcare
Switzerland's Alcon Abandons Lensar Deal as US Antitrust Hurdles Persist - marketscreener.com
Alcon terminates LENSAR acquisition after FTC opposition By Investing.com - Investing.com Australia
Lensar, Alcon terminate merger after FTC opposition By Investing.com - Investing.com Canada
Alcon Buy Rating Reaffirmed, Despite Failed STAAR Merger, As Eyecare Portfolio Leads - Seeking Alpha
Alcon, LENSAR agree to terminate merger agreement - MLex
Alcon (ALC) and Lensar Call Off Merger Agreement - GuruFocus
Alcon (ALC) Ends Merger Talks with Lensar, Impacting Both Stocks - GuruFocus
Lensar (LNSR) and Alcon (ALC) Terminate Merger Agreement Amid FT - GuruFocus
Lensar, Alcon terminate merger after FTC opposition - Investing.com
Lensar announces termination of merger agreement with Alcon Research, LLC - marketscreener.com
Alcon terminates LENSAR acquisition after FTC opposition - Investing.com
Lensar® Announces Termination Of Merger Agreement With Alcon Research, Llc - TradingView
Lensar and Alcon Agree to Terminate Merger - marketscreener.com
Alcon and Lensar agree to terminate merger agreement - marketscreener.com
Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement - Business Wire
Eye-surgery laser maker LENSAR drops Alcon deal after FTC move to enjoin merger - Stock Titan
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
Alcon Inc Stock (ISIN: CH0432492467) Eyes 20% Upside as Analysts Weigh Momentum Against Healthcare H - AD HOC NEWS
Alcon Inc Stock (ISIN: CH0432492467) Faces Headwinds Amid Analyst Optimism and Buyback Momentum - AD HOC NEWS
STAAR Surgical jumps after Alcon raises offer to $30.75/share in cash (update) - MSN
Futures Contracts for Alcon Futures - TradingView
Alcon Inc Stock (ISIN: CH0432492467) Holds Steady Amid Eye Care Sector Resilience - AD HOC NEWS
UBS reiterates Buy on Alcon stock, sees earnings beats ahead - Investing.com Nigeria
ALC.SW Alcon Inc. (SIX) closes CHF62.56 on 11 Mar 2026: watch analyst targets - Meyka
RSI Check: Will Alcon Inc benefit from green energy policiesTrade Exit Summary & Long-Term Capital Growth Ideas - baoquankhu1.vn
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
UBS names Alcon top pick, sees strong catalyst path ahead - Investing.com South Africa
UBS reiterates Buy on Alcon stock, sees earnings beats ahead By Investing.com - Investing.com Australia
Finanzdaten der Alcon Inc-Aktie (ALC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
2.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):